HK1004066A1 - Immunosuppressive compounds - Google Patents

Immunosuppressive compounds Download PDF

Info

Publication number
HK1004066A1
HK1004066A1 HK98103136A HK98103136A HK1004066A1 HK 1004066 A1 HK1004066 A1 HK 1004066A1 HK 98103136 A HK98103136 A HK 98103136A HK 98103136 A HK98103136 A HK 98103136A HK 1004066 A1 HK1004066 A1 HK 1004066A1
Authority
HK
Hong Kong
Prior art keywords
straight
carbon atoms
hydrogen
alkyl
alkenyl
Prior art date
Application number
HK98103136A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1004066B (en
Inventor
M. Armistead David
S. Boger Joshua
V. Meyers Harold
O. Saunders Jeffrey
D. Tung Roger
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24186237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1004066(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of HK1004066B publication Critical patent/HK1004066B/en
Publication of HK1004066A1 publication Critical patent/HK1004066A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/56—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
HK98103136A 1990-07-02 1991-07-02 Immunosuppressive compounds HK1004066A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/547,814 US5192773A (en) 1990-07-02 1990-07-02 Immunosuppressive compounds
US547814 1990-07-02
PCT/US1991/004694 WO1992000278A1 (en) 1990-07-02 1991-07-02 Novel immunosuppressive compounds

Publications (2)

Publication Number Publication Date
HK1004066B HK1004066B (en) 1998-11-13
HK1004066A1 true HK1004066A1 (en) 1998-11-13

Family

ID=24186237

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98103136A HK1004066A1 (en) 1990-07-02 1991-07-02 Immunosuppressive compounds

Country Status (16)

Country Link
US (5) US5192773A (https=)
EP (1) EP0537269B1 (https=)
JP (2) JP3095247B2 (https=)
KR (1) KR100197306B1 (https=)
AT (1) ATE159247T1 (https=)
AU (2) AU660623B2 (https=)
BR (2) BR1100732A (https=)
CA (1) CA2086428A1 (https=)
DE (1) DE69127970T2 (https=)
DK (1) DK0537269T3 (https=)
ES (1) ES2109269T3 (https=)
GR (1) GR3025918T3 (https=)
HK (1) HK1004066A1 (https=)
SG (1) SG49663A1 (https=)
TW (1) TW215055B (https=)
WO (1) WO1992000278A1 (https=)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5192773A (en) * 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
US5620971A (en) * 1991-05-09 1997-04-15 Vertex Pharmaceuticals Incorporated Biologically active acylated amino acid derivatives
US5723459A (en) * 1991-05-09 1998-03-03 Vertex Pharmaceuticals Incorporated Biologically active acylated amino acid derivatives
ES2137186T3 (es) * 1991-05-09 1999-12-16 Vertex Pharma Nuevos compuestos inmunosupresores.
MX9202466A (es) * 1991-05-24 1994-06-30 Vertex Pharma Compuestos inmunosupresores novedosos.
CA2091194A1 (en) * 1992-04-08 1993-10-09 Richard D. Connell 2-oxo-ethyl derivatives as immunosuppressants
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
NZ314207A (en) * 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
US5846981A (en) * 1993-05-28 1998-12-08 Gpi Nil Holdings Inc. Inhibitors of rotamase enzyme activity
US5798355A (en) * 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
ES2065290B1 (es) * 1993-07-29 1995-11-01 Consejo Superior Investigacion Utilizacion de inhibidores enzimaticos para el tratamiento de enfermedades causadas por parasitos.
US6566386B2 (en) 1993-08-09 2003-05-20 Nippon Zoki Pharmaceutical Co., Ltd. Immunomodulating and antiinflammatory agent
JP3193205B2 (ja) * 1993-08-09 2001-07-30 日本臓器製薬株式会社 好酸球増多抑制剤
US5453431A (en) * 1993-10-29 1995-09-26 Gilman; Andrew L. Use of hydroxychloroquine for treatment of graft-versus-host disease
ES2101420T3 (es) * 1993-11-02 1997-07-01 Hoechst Ag Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
NZ270267A (en) * 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
US5898029A (en) * 1994-04-12 1999-04-27 The John Hopkins University Direct influences on nerve growth of agents that interact with immunophilins in combination with neurotrophic factors
US6150527A (en) * 1994-08-18 2000-11-21 Ariad Pharmaceuticals, Inc. Synthetic multimerizing agents
US6133456A (en) * 1994-08-18 2000-10-17 Ariad Gene Therapeutics, Inc. Synthetic multimerizing agents
US20030036654A1 (en) * 1994-08-18 2003-02-20 Holt Dennis A. Synthetic multimerizing agents
US6277372B1 (en) 1994-11-08 2001-08-21 Diacrin, Inc. Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases
US6294383B1 (en) 1994-11-08 2001-09-25 The Mclean Hospital Corporation Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases
US6204053B1 (en) * 1994-11-08 2001-03-20 Diacrin, Inc. Porcine cortical cells and their use in treatment of neurological deficits due to neurodegenerative diseases
US5543423A (en) * 1994-11-16 1996-08-06 Vertex Pharmaceuticals, Incorporated Amino acid derivatives with improved multi-drug resistance activity
US5726184A (en) * 1995-05-19 1998-03-10 Vertex Pharmaceuticals Incorporated Tetralin compounds with improved MDR activity
US6509477B1 (en) 1998-11-12 2003-01-21 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme activity
GB2324527B (en) * 1995-06-07 1999-12-22 Guilford Pharm Inc Small molecule inhibitors of rotamase enzyme activity
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
AT500192B1 (de) * 1995-06-07 2008-05-15 Guilford Pharm Inc Neurotrophe verbindung, diese enthaltende pharmazeutische masse, verwendung der verbindung und verfahren zu ihrer herstellung
US6291510B1 (en) 1995-06-07 2001-09-18 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US7056935B2 (en) * 1995-06-07 2006-06-06 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5614547A (en) * 1995-06-07 1997-03-25 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
AT500193B1 (de) * 1995-06-07 2007-11-15 Guilford Pharm Inc Neurotrophe verbindung und verfahren zu ihrer herstellung
US6037370A (en) 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
JPH0959180A (ja) 1995-08-11 1997-03-04 Nippon Zoki Pharmaceut Co Ltd 活性化免疫グロブリン
IL135495A (en) * 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
US5801197A (en) * 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
JP3089350B2 (ja) 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤
US5717092A (en) * 1996-03-29 1998-02-10 Vertex Pharmaceuticals Inc. Compounds with improved multi-drug resistance activity
DE19616509A1 (de) * 1996-04-25 1998-01-15 Asta Medica Ag Neue spezifische Immunophilin-Liganden als Antiasthmatika, Immunsuppressiva
US6218424B1 (en) 1996-09-25 2001-04-17 Gpi Nil Holdings, Inc. Heterocyclic ketone and thioester compounds and uses
US5786378A (en) * 1996-09-25 1998-07-28 Gpi Nil Holdings, Inc. Heterocyclic thioesters
US5801187A (en) * 1996-09-25 1998-09-01 Gpi-Nil Holdings, Inc. Heterocyclic esters and amides
US5811434A (en) * 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
US5780484A (en) * 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
NZ335480A (en) * 1996-12-31 2001-04-27 Guilford Pharm Inc Neurotrophic low molecular weight N-linked sulfonamides of heterocyclic thioesters and their use as inhibitors of immunophilin proteins
SK57899A3 (en) * 1996-12-31 2000-05-16 Guilford Pharm Inc N-linked ureas and carbamates of heterocyclic thioesters
US5935989A (en) * 1996-12-31 1999-08-10 Gpi Nil Holdings Inc. N-linked ureas and carbamates of heterocyclic thioesters
US5874449A (en) * 1996-12-31 1999-02-23 Gpi Nil Holdings, Inc. N-linked sulfonamides of heterocyclic thioesters
JPH10212246A (ja) 1997-01-30 1998-08-11 Nippon Zoki Pharmaceut Co Ltd 経口投与用製剤
US5846979A (en) * 1997-02-28 1998-12-08 Gpi Nil Holdings, Inc. N-oxides of heterocyclic esters, amides, thioesters, and ketones
US6187784B1 (en) 1998-06-03 2001-02-13 Gpi Nil Holdings, Inc. Pipecolic acid derivative hair growth compositions and uses
US20010049381A1 (en) * 1997-06-04 2001-12-06 Gpl Nil Holdings, Inc., Pyrrolidine derivative hair growth compositions and uses
US6274602B1 (en) * 1998-06-03 2001-08-14 Gpi Nil Holdings, Inc. Heterocyclic thioester and ketone hair growth compositions and uses
US5945441A (en) * 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
US6271244B1 (en) 1998-06-03 2001-08-07 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses
US6187796B1 (en) 1998-06-03 2001-02-13 Gpi Nil Holdings, Inc. Sulfone hair growth compositions and uses
US6852496B1 (en) * 1997-08-12 2005-02-08 Oregon Health And Science University Methods of screening for agents that promote nerve cell growth
DE19742263A1 (de) * 1997-09-25 1999-04-01 Asta Medica Ag Neue spezifische Immunophilin-Liganden als Antiasthmatika, Antiallergika, Antirheumatika, Immunsuppressiva, Antipsoriatika, Neuroprotektiva
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
AU743199B2 (en) * 1998-06-02 2002-01-24 Bristol-Myers Squibb Company Neurotrophic difluoroamide agents
US6172087B1 (en) 1998-06-03 2001-01-09 Gpi Nil Holding, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
US6262055B1 (en) 1998-06-03 2001-07-17 Merck & Co., Inc. HIV integrase inhibitors
CA2333964A1 (en) * 1998-06-03 1999-12-09 Gpi Nil Holdings, Inc. Aza-heterocyclic compounds used to treat neurological disorders and hair loss
US6380249B1 (en) 1998-06-03 2002-04-30 Merck & Co., Inc. HIV integrase inhibitors
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
WO1999062881A1 (en) * 1998-06-03 1999-12-09 Gpi Nil Holdings, Inc. Aza-heterocyclic compounds used to treat neurological disorders and hair loss
US6429215B1 (en) 1998-06-03 2002-08-06 Gpi Nil Holdings, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
EP1842845B1 (en) * 1998-06-03 2014-07-16 GliaMed, Inc. Aza-heterocyclic compounds used to treat neurological disorders and hair loss
US6306891B1 (en) 1998-06-03 2001-10-23 Merck & Co., Inc. HIV integrase inhibitors
CN1295561A (zh) 1998-06-03 2001-05-16 Gpinil控股公司 N－杂环羧酸或羧酸等排物的n－结合氨磺酰
WO1999062513A1 (en) * 1998-06-03 1999-12-09 Merck & Co., Inc. Hiv integrase inhibitors
ZA9811063B (en) * 1998-06-03 2000-07-07 Guilford Pharm Inc Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds.
EP1085853A1 (en) * 1998-06-03 2001-03-28 GPI NIL Holdings, Inc. Heterocyclic ester and amide hair growth compositions and uses
PT1098897E (pt) 1998-07-17 2004-10-29 Agouron Pharma Compostos composicoes e metodos para estimular o crescimento e a elongacao neuronal
AU756627B2 (en) 1998-07-27 2003-01-16 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Diketoacid-derivatives as inhibitors of polymerases
GB9816358D0 (en) * 1998-07-27 1998-09-23 Angeletti P Ist Richerche Bio Enzyme inhibitors
US6395758B1 (en) 1998-08-14 2002-05-28 Gpi Nil Holdings, Inc. Small molecule carbamates or ureas for vision and memory disorders
US6337340B1 (en) 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
EP1105112A2 (en) * 1998-08-14 2001-06-13 GPI NIL Holdings, Inc. Compositions and uses for vision and memory disorders
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6399648B1 (en) 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US6335348B1 (en) 1998-08-14 2002-01-01 Gpi Nil Holdings, Inc. Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders
US6506788B1 (en) 1998-08-14 2003-01-14 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders
US6384056B1 (en) 1998-08-14 2002-05-07 Gpi Nil Holdings, Inc. Heterocyclic thioesters or ketones for vision and memory disorders
US7338976B1 (en) * 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
US7265150B1 (en) * 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6333340B1 (en) 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6462072B1 (en) * 1998-09-21 2002-10-08 Gpi Nil Holdings, Inc. Cyclic ester or amide derivatives
US6444205B2 (en) 1998-09-30 2002-09-03 Diacrin, Inc. Transplantation of neural cells for the treatment of chronic pain or spasticity
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6228872B1 (en) 1998-11-12 2001-05-08 Bristol-Myers Squibb Company Neurotrophic diamide and carbamate agents
JP2000143536A (ja) 1998-11-13 2000-05-23 Nippon Zoki Pharmaceut Co Ltd 抗浮腫剤
JP3929244B2 (ja) 1998-12-25 2007-06-13 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する芳香族ヘテロ環誘導体
US20020006901A1 (en) * 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
US6734211B1 (en) 1999-07-09 2004-05-11 Oregon Health & Sciences University Compositions and methods for promoting nerve regeneration
WO2001017953A1 (en) 1999-09-08 2001-03-15 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
ATE282953T1 (de) * 1999-09-20 2004-12-15 Charlotte Mecklenburg Hospital Lösung zur konservierung von herzen
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
US6818643B1 (en) 1999-12-08 2004-11-16 Bristol-Myers Squibb Company Neurotrophic bicyclic diamides
US20030130298A1 (en) * 1999-12-21 2003-07-10 Chapdelaine Marc Jerome Cd45 inhibitors
CA2393466C (en) 1999-12-21 2010-01-19 Gpi Nil Holdings, Inc. Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
JP2003518085A (ja) * 1999-12-21 2003-06-03 アストラゼネカ アクチボラグ Ｃｄ４５阻害剤
EP1125925A1 (en) * 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amine derivatives for the treatment of apoptosis
US7288551B1 (en) 2000-09-19 2007-10-30 Charlotte-Mecklenburg Hospital Authority Solution for the preservation of hearts
JP2004532187A (ja) 2001-01-25 2004-10-21 ギルフォード ファーマシュウティカルズ インコーポレイテッド 三置換カルボサイクリックサイクロフィリン結合化合物とその用途
US6593362B2 (en) 2001-05-21 2003-07-15 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
WO2002096420A2 (en) * 2001-05-29 2002-12-05 Guilford Pharmaceuticals Inc. Method for treating nerve injury caused by surgery
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
WO2003062773A1 (en) * 2002-01-24 2003-07-31 Pei Electronics, Inc. Compact integrated infrared scene projector
WO2003105697A1 (en) * 2002-06-14 2003-12-24 Loma Linda University Medical Center Vascular wound closure device and method
US8163726B2 (en) * 2002-09-18 2012-04-24 University Of Pennsylvania Method of inhibiting choroidal neovascularization
CA2539324A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US20060189551A1 (en) * 2004-10-04 2006-08-24 Duke University Combination therapies for fungal pathogens
US20060194829A1 (en) * 2004-12-20 2006-08-31 Clackson Timothy P Therapeutic materials and methods
JP4974903B2 (ja) * 2005-02-09 2012-07-11 参天製薬株式会社 疾患または状態を処置するための液体処方物
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
EP2671507A3 (en) 2005-04-28 2014-02-19 Proteus Digital Health, Inc. Pharma-informatics system
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
PL2001466T3 (pl) 2006-03-23 2016-06-30 Santen Pharmaceutical Co Ltd Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
US7943775B2 (en) * 2006-06-21 2011-05-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Small molecules for imaging protein-protein interactions
MX2009002893A (es) 2006-09-18 2009-07-10 Raptor Pharmaceutical Inc Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
US20080306098A1 (en) * 2006-11-06 2008-12-11 Mutz Mitchell W Pharmacokinetics of protease inhibitors and other drugs
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US20090054334A1 (en) * 2007-05-23 2009-02-26 Mutz Mitchell W Combinatorial improvement of bifunctional drug properties
US20090053245A1 (en) * 2007-05-29 2009-02-26 Mutz Mitchell W Pharmacokinetics and Efficacy of Anti-Angiogenic Drugs and Drugs Treating Diseases of the Blood
WO2009055042A1 (en) * 2007-10-24 2009-04-30 Amplyx Pharmaceuticals, Inc. Enhancing the efficacy of anti-infective therapeutics
IL255113B (en) 2009-05-06 2022-09-01 Laboratory Skin Care Inc Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
MX2012002910A (es) 2009-09-11 2012-04-19 Vertex Pharma Composiciones de n-bencil-3-(4-clorofenil)-2-[metil-[2-oxo-2-(3,4, 5-trietoxifenil)acetil]amino]-n-[3-(4-piridil)-1-[2-(4-piridil)et il]propil]propanamida y usos de las misma.
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
EP2705856A1 (en) 2012-09-07 2014-03-12 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. Compounds for the treatment of neurodegenerative disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3646061A (en) * 1968-06-10 1972-02-29 Ajinomoto Kk Method of preparing n-alkoxalyl and n-formyl derivatives of alpha-amino acid esters
DE2328391A1 (de) * 1972-06-19 1974-01-10 Degussa Trialkoxycinnamoylaminocarbonsaeuren
CN86101850A (zh) * 1985-03-22 1987-02-04 森得克斯(美国)有限公司 N，n′-二烷基胍基二肽的制造方法与用途
DE4015255A1 (de) * 1990-05-12 1991-11-14 Hoechst Ag Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase
US5192773A (en) * 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds

Also Published As

Publication number Publication date
WO1992000278A1 (en) 1992-01-09
GR3025918T3 (en) 1998-04-30
ES2109269T3 (es) 1998-01-16
AU660623B2 (en) 1995-07-06
JPH06501457A (ja) 1994-02-17
JP3360054B2 (ja) 2002-12-24
AU8285591A (en) 1992-01-23
BR1100732A (pt) 2000-06-06
BR1100764A (pt) 2000-02-08
JP2000143599A (ja) 2000-05-23
EP0537269A1 (en) 1993-04-21
DE69127970T2 (de) 1998-03-05
DK0537269T3 (da) 1998-06-02
KR930701403A (ko) 1993-06-11
TW215055B (https=) 1993-10-21
ATE159247T1 (de) 1997-11-15
US5330993A (en) 1994-07-19
US5516797A (en) 1996-05-14
DE69127970D1 (de) 1997-11-20
JP3095247B2 (ja) 2000-10-03
AU692915B2 (en) 1998-06-18
EP0537269B1 (en) 1997-10-15
AU3309395A (en) 1996-01-11
US5192773A (en) 1993-03-09
SG49663A1 (en) 1998-06-15
CA2086428A1 (en) 1992-01-03
KR100197306B1 (ko) 1999-06-15
US5622970A (en) 1997-04-22
US5665774A (en) 1997-09-09

Similar Documents

Publication Publication Date Title
EP0537269B1 (en) Immunosuppressive compounds
HK1004066B (en) Immunosuppressive compounds
EP0584223B1 (en) Novel immunosuppressive compounds
WO1992021313A2 (en) Novel immunosuppressive compounds
US5686424A (en) 2-oxoethyl derivatives as immunosuppressants
US5620971A (en) Biologically active acylated amino acid derivatives
US5385918A (en) Aminomethylene-peptides as immunosuppressants
WO1992004370A1 (en) Modified di- and tripeptidyl immunosuppressive compounds
US5723459A (en) Biologically active acylated amino acid derivatives
PL152507B1 (en) Method of obtaining novel derivatives of straight amides
EP0542554B1 (en) Substituted N-biphenylyl lactams
HK1013994B (en) Novel immunosuppressive compounds
US6469038B1 (en) Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
US5591748A (en) Immunomodulatory azaspiranes
US4221914A (en) Alpha-halomethyl derivatives of histamine and related compounds
US4307099A (en) Reaction products of pyrazolo[1,5-c]quinazoline derivatives and proline derivatives and methods for reducing blood pressure while inhibiting allergic reactions with them

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100702